Literature DB >> 7862206

Nicotine as a therapeutic drug.

E C Westman1, E D Levin, J E Rose.   

Abstract

Current evidence about the therapeutic potential of nicotine is strongest for ulcerative colitis. The role, if any, of nicotine therapy in Parkinson's or Alzheimer's diseases is not clear, but further research appears warranted. We need more information about the tolerability and safety of nicotine administration in such diseases. At present, any therapeutic trials of nicotine therapy should occur only as part of research protocols. Further nonjudgmental examination of the perceived effects of tobacco use may lead to other uses of nicotine. However, given the widespread morbidity and mortality directly attributable to tobacco use, no form of tobacco should be used to deliver nicotine. We encourage everyone who uses tobacco products to quit.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7862206

Source DB:  PubMed          Journal:  N C Med J        ISSN: 0029-2559


  3 in total

1.  (E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa.

Authors:  Tanja Spoettl; Christine Paetzel; Hans Herfarth; Merouane Bencherif; Juergen Schoelmerich; Roland Greinwald; Gregory J Gatto; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2006-05-20       Impact factor: 2.571

2.  Nicotine effects on adults with attention-deficit/hyperactivity disorder.

Authors:  E D Levin; C K Conners; E Sparrow; S C Hinton; D Erhardt; W H Meck; J E Rose; J March
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

3.  Nicotine dependence: development, mechanisms, individual differences and links to possible neurophysiological correlates.

Authors:  Ernest Groman; Karl Fagerström
Journal:  Wien Klin Wochenschr       Date:  2003-03-31       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.